Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.77 |
| ▸ | CA2 | P00918 | 8/20 | 0.77 |
| ▸ | CA9 | Q16790 | 4/20 | 0.69 |
| ▸ | CA12 | O43570 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13401868 | 0.85 | NPC1 (0.70) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL30628487 | 0.84 | CA1 (0.86) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL6046379 | 0.84 | MEN1 (0.90) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL11807861 | 0.83 | MEN1 (0.87) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL11624989 | 0.80 | CA1 (0.75) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL11711747 | 0.80 | NPC1 (0.64) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL8868584 | 0.79 | CA2 (0.86) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL11627590 | 0.78 | ALDH1A1 (0.51) | CA1CA2TDP1L3MBTL1 | |
| SCHEMBL11627596 | 0.78 | FLT1 (0.52) | CA1CA2L3MBTL1NLRP3 | |
| SCHEMBL4305965 | 0.78 | CA1 (0.89) | CA1CA2CA9CA12MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785499-B2 | Targeting NAD biosynthesis in bacterial pathogens | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785499-B2 | Targeting NAD biosynthesis in bacterial pathogens | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120190708-A1 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190708-A1 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190708-A1 | TARGETING NAD BIOSYNTHESIS IN BACTERIAL PATHOGENS | NAMPT, NAPRT, NADK | CA1 4859/4885CA2 4445/4885CA9 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.